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Abstract
Purpose Uncoated self-expanding nitinol stents (NS) are
commonly oversized in peripheral arteries. In current
practice, 1-mm oversizing is recommended. Yet, oversiz-
ing of NS may be associated with increased restenosis. To
provide further evidence, NS were implanted in porcine
iliofemoral arteries with a stent-to-artery-ratio between 1.0
and 2.3. Besides conventional uncoated NS, a novel self-
expanding NS with an antiproliferative titanium-nitride-
oxide (TiNOX) coating was tested for safety and efficacy.
Methods Ten uncoated NS and six TiNOX-coated NS
(5–6 mm) were implanted randomly in the iliofemoral
artery of six mini-pigs. After implantation, quantitative
angiography (QA) was performed for calculation of artery
and minimal luminal diameter. Follow-up was performed
by QA and histomorphometry after 5 months.
Results Stent migration, stent fracture, or thrombus for-
mation were not observed. All stents were patent at follow-
up. Based on the location of the stent (iliac/femoral) and
the stent-to-artery-ratio, stent segments were divided into
‘‘normal-sized’’ (stent-to-artery-ratio \ 1.4, n = 12) and
‘‘oversized’’ (stent-to-artery-ratio C 1.4, n = 9). All stent
segments expanded to their near nominal diameter during
follow-up. Normal-sized stent segments increased their
diameter by 6% and oversized segments by 29%. A sig-
nificant correlation between oversizing and restenosis by
both angiography and histomorphometry was observed.
Restenosis rates were similar for uncoated NS and TiNOX-
coated NS.
Conclusions TiNOX-coated NS are as safe and effective
as uncoated NS in the porcine iliofemoral artery. All stents
further expand to near their nominal diameter during fol-
low-up. Oversizing is linearly and positively correlated
with neointimal proliferation and restenosis, which may not
be reduced by TiNOX-coating.
Keywords Catheterization, peripheral  Stent  Nitinol 
Titanium-nitride-oxide  Porcine
Introduction
Restenosis is the main drawback of endovascular treatment
of the iliac and femoral arteries [1–4]. Conflicting experi-
mental and clinical results have been reported for patency
rates and restenosis in the iliofemoral arteries with different
stent designs [5–8]. Currently, self-expanding nitinol stents
are used for the treatment of peripheral artery disease. Self-
expanding stents are commonly oversized to ensure opti-
mal wall apposition and to prevent stent migration [8, 9]. In
practice, 1-mm oversizing is usually recommended. How-
ever, stent oversizing, determined as the ratio of nominal
stent diameter to vessel diameter at implantation, may
cause significant neointimal proliferation and restenosis
mainly in the superficial femoral arteries, but also in iliac
arteries as reported in a recent porcine study [8].
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Titanium-nitride-oxide-coated stents (TiNOX) are
biologically inert compared with the nickel component of
nitinol stents and can significantly reduce neointimal
hyperplasia in coated stainless steel stents [10]. Data about
self-expanding TiNOX-coated stents in the iliofemoral
arterial bed are scarce. Thus, the purpose of the present
study was to test safety and efficacy of self-expanding
TiNOX-coated nitinol stents in direct comparison to self-
expanding uncoated nitinol stents in porcine iliofemoral
arteries, investigating the impact of stent oversizing on
restenosis and long-term outcome.
Materials and Methods
This prospective, controlled animal study was approved by
the local animal ethical committee. It conforms to the
guidelines established in the ‘‘Position of the American
Heart Association on Research Animal Use’’ adopted by
the American Heart Association on November 11, 1984.
We used self-expanding uncoated peripheral nitinol stents
(n = 10) and self-expanding TiNOX-coated peripheral
nitinol stents (n = 6).
TiNOX stents feature a flexible helicoidal stainless steel
shaft with open cell design and a smooth electropolish
finish. The thin coating consists of a titanium-nitride-oxide
alloy. It functions as a barrier minimizing the leakage of
metal residues, mostly nickel, into the arterial wall and
attenuating electrical conductivity. This feature potentially
minimizes cytotoxicity and provides beneficial effects on
hemocompatibility. The stent is enclosed within a sheath
before deployment at the target lesion. Implanted stents
had the following sizes, as provided by the manufacturers
(Biotronik AG, Bu¨lach, Switzerland; Hexacath SA, Paris,
France): 5 9 30-mm, 6 9 40-mm, and 6 9 60-mm. They
were implanted in six mini-pigs of either sex (body weight
45 kg), depending on the size and anatomy of the ilio-
femoral arterial bed. Stent implantation was randomized to
prevent implantation bias. Stent oversizing was determined
as the ratio of nominal stent diameter to artery diameter at
implantation (stent-to-artery ratio = oversizing ratio). We
set the cutoff for relevant oversizing at an oversizing ratio
of C1.4, as suggested by Zhao et al. [8]. Stents were
divided into ‘‘normal-sized’’ and ‘‘oversized’’ at this cutoff
point. Four animals received three stents each, one stent in
the right external iliac artery and one stent in the left
external iliac artery, respectively. The third stent was either
placed in the right or left superficial femoral artery. In two
animals, one stent was placed in the right external iliac
artery and the other stent in the left external iliac artery,
respectively. Six stents (4 uncoated nitinol stents and 2
TiNOX-coated stents) were overlapping a bifurcation with
a significant reduction in vessel diameter distal to the
bifurcation. Stent-to-artery ratio was C1.4 distal and \1.4
proximal to the bifurcation. Accordingly, these stents were
divided into a proximal and distal segment and each seg-
ment was analyzed separately.
Stent implantation was performed under general anes-
thesia, which was induced with sodium pentobarbital
10 mg/kg intravenously (IV) and maintained by halothane
inhalation [10, 11]. The left carotid artery was dissected
free and a 6-French vascular sheath was placed and sutured
into position to perform selective angiography and stent
placement into the right and left iliofemoral arteries. Stent
distribution was homogenous among the animals. No stent
overlapping was performed. After implantation, the ani-
mals were given a loading dose of 250 mg of acetylsali-
cylic acid and then transported on the same day back to the
farm, where they were housed for 5 months. After this
period, pigs were brought back to the hospital and a second
angiography under general anesthesia was performed in all
animals. Immediately after angiography, animals were
euthanized by using potassium chloride. The iliofemoral
arteries were removed subsequently. The arteries with the
stents were dissected and fixed in 300 ml of buffered 4%
formaldehyde. Four weeks after fixation, the stents were
embedded in polymethylmethacrylate and cut with a spe-
cial microtome into 800-lm-thin slices and polished to a
thickness of 100 lm. All sections were prepared for light
microscopy by staining with Paragon (7.3 g toluidine blue
with basic fuchsin dissolved in 1,000 ml 30% ethanol)
under prewarming (90C for 15 s).
Quantitative Angiography
All angiograms were assessed quantitatively by a standard
software program (Medis SA, Medical Imaging Systems,
Leiden, The Netherlands; Fig. 1) [12]. Minimal lumen
diameter (MLD) and the proximal and distal reference
diameters were measured quantitatively. Late loss was
calculated by subtracting MLD at follow-up from MLD at
baseline. In-stent restenosis was calculated from MLD
divided by the reference diameter multiplied by 100 as
previously described [10–12].
Histomorphometry
After staining of the samples with Paragon, quantitative
evaluation of the stented vessels was performed by using
the Image-pro plus digital system (Media Cybernetics, Inc.,
Bethesda, MD) as previously described [11].
Histological evaluation was performed by a blinded
observer (NH) unaware of the location or coating status of
the stent (Fig. 2). Within the stented iliofemoral segments,
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two sections were examined. The following parameters
were determined:
1. Vessel lumen, intimal proliferation, and stent lumen
(vessel lumen plus intimal proliferation). Mean and
median values, as well as standard deviations were
calculated for each stent section, as appropriate.
2. Intimal proliferation was calculated from the stent
lumen minus the vessel lumen (mm2) and in-stent
restenosis from intimal proliferation divided by the
stent lumen multiplied by 100.
3. Reendothelialization was assessed under high-magni-
fication light microscopy. In all sections, inflammation
was visually assessed.
Statistical Analysis
Continuous variables are expressed as mean ± standard
deviation or median with ranges as appropriate. Intergroup
comparisons were performed by two-tailed Student’s t test
or Mann–Whitney test as appropriate. Within-group anal-
yses at different time points were performed by two-tailed
paired Student’s t test. Categorical variables are reported as
counts and percentages and were compared by Fisher’s
exact test. Linear regressions were used for data analysis in
dot-plots. N numbers represents stent segments. Statistical
significance was assumed with a two-sided P value \ 0.05.
All data were analyzed using GraphPad Prism, version 5.
Results
All animals survived the intervention and the follow-up
interval of 5 months without any clinical symptoms. One
TiNOX-coated stent could not be retrieved from the animal
and was therefore excluded from the study. In total, 21
stent segments were analyzed (uncoated nitinol n = 14,
TiNOX-coated n = 7). Of these, 12 stent segments were
normal-sized and 9 were oversized. No significant differ-
ence was observed in average nominal stent diameter
between the uncoated nitinol stents (range 5–6 mm; med-
ian 6 mm) and TINOX-coated stents (range 5–6 mm;
median 6 mm; P = 1). Stent migration, stent fracture, or
thrombus formation were not observed in either group. All
stented artery segments were patent at 5 months (Fig. 1).
The oversizing ratio ranged from 1.0 to 2.3. The mean
oversizing ratio was 1.1 ± 0.1 in the normal and 1.7 ± 0.3
in the oversized group (P \ 0.001). Six (29%) stent seg-
ments in the uncoated nitinol group were oversized and
three (14%) stent segments in the TiNOX group (P = 1;
Table 1). No significant difference in oversizing ratios
between uncoated self-expanding stent segments and
TINOX-coated stent segments existed (1.4 ± 0.4 mm vs.
1.31 ± 0.4 mm; P = 0.58).
At baseline, the stent segments had a mean implantation
diameter of 4.4 ± 1.0 mm (range 2.6–6.2 mm; median
4.4 mm), not fully expanded to their median nominal
diameter of 6 mm. Five months after implantation, all stent
segments increased in diameter to 5.1 ± 0.6 mm under the
outward self-expanding force (5.4 ± 0.5 mm for the
normal-sized, P = 0.002 vs. baseline, and 4.8 ± 0.6 mm
for the oversized group, P \ 0.001 vs. baseline; Table 1).
Yet, mean stent expansion was less in the normal-sized
compared with the oversized group (0.3 ± 0.2 mm, 6% vs.
1.4 ± 0.7 mm, 29%; P = 0.001). The changes in angio-
graphic stent diameter for 21 individual stent segments
immediately after implantation (0 day) and 5 months after
implantation are shown in Fig. 3. As expected, arteries
Fig. 1 Comparison of angiographic images at baseline and 5-month
follow-up shows differences of in-stent restenosis at 5 months
between normal-sized and oversized stent segments (lean arrows
indicate normal-sized stent segments, bold arrows indicate oversized
stent segments)
Fig. 2 Histologic micrographs (Paragon staining) at 5 months shows
differences of in-stent restenosis between normal and oversized stent
segments for uncoated nitinol stents (left) and titanium-nitride-oxide-
coated nitinol stents (right). Magnification 109
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before stenting were larger in the normal-sized than in the
oversized segments (5.1 ± 0.6 mm vs. 3.4 ± 0.5 mm,
P \ 0.001). At baseline, MLD was 4.9 ± 0.7 mm in the
normal-sized and 3.5 ± 0.9 in the oversized stent group
(P = 0.002). After 5 months, angiographic MLD was less
than baseline MLD in uncoated self-expanding stents
segments but also in TINOX-coated stent segments
(Table 1). MLD at follow-up was 4.4 ± 0.7 mm in the
normal-sized and 2.0 ± 1.0 in the oversized stent group
(P \ 0.001; Table 1). A certain amount of in-stent reste-
nosis due to neointimal proliferation was observed in all
stent segments. However, angiographic in-stent restenosis
was less pronounced in the normal-sized compared with
the oversized stent segments (13 ± 6%, range 3–28 vs.
48 ± 17%, range 25–66; P \ 0.001; Fig. 4). Accordingly,
late loss was less in the normal stent group than in the
oversized stent group (0.6 ± 0.3 mm vs. 1.6 ± 0.7 mm,
P \ 0.001). No significant differences between uncoated
self-expanding stents segments and TiNOX-coated stent
segments were observed (29 ± 23% vs. 25 ± 19%,
P = 0.67; Fig. 4). Representative angiographic and histo-
morphometric images of uncoated self-expanding and
TiNOX-coated stents divided into normal-sized and over-
sized segments are shown in Figs. 1 and 2. Three stent
segments (1 normal-sized uncoated, 1 oversized uncoated,
and 1 normal-sized TiNOX-coated stent segment) could
not be analyzed by histomorphometry due to technical
problems. Histological examination of all other stent seg-
ments (n = 18) showed fully endothelialized neointimal
layers covering the inner layer of neointimal proliferation.
No significant inflammation was found. Corresponding to
the angiographic results, the oversized stent segments of
both stent types displayed a similar degree of remarkable
lumen narrowing and in-stent restenosis due to neointimal
proliferation by histology (18 ± 7%, range 8–27% for
normal-sized vs. 52 ± 23%, range 23–88% for oversized,
Table 1 Angiographic and histomorphometric data for normal-sized (n = 12) and oversized (n = 9) stent segments with comparison for
uncoated self-expanding stent segments (n = 14) and titanium-nitride-oxide-coated stent segments (n = 7)
Normal-sized Oversized
ALL (12) UNS (8) TINOX (4) ALL (9) UNS (6) TINOX (3)
MLD BL (mm) 4.9 ± 0.7 4.6 ± 0.7 5.2 ± 0.5 3.5 ± 0.9* 3.8 ± 1.0*, 3.0 ± 0.3*
MLD FU (mm) 4.4 ± 0.7 4.0 ± 0.8 4.6 ± 0.7 2.0 ± 1.0* 1.9 ± 1.2*, 2.0 ± 0.7*
Artery diameter at BL (mm) 5.1 ± 0.6 5.0 ± 0.7 5.3 ± 0.5 3.4 ± 0.5* 3.3 ± 0.5*, 3.6 ± 0.5*
Stent diameter at FU (mm) 5.4 ± 0.5 5.3 ± 0.6 5.6 ± 0.3 4.8 ± 0.6* 4.5 ± 0.5*, 5.4 ± 0.4
Stent expansion at FU (mm) 0.3 ± 0.2§ 0.3 ± 0.2,§ 0.3 ± 0.3 1.4 ± 0.7*,§ 1.2 ± 0.8*,,§ 1.7 ± 0.1*
Oversizing ratio 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.7 ± 0.3* 1.8 ± 0.3*, 1.7 ± 0.3*
Angiographic late loss (mm) 0.6 ± 0.3 0.6 ± 0.4 0.6 ± 0.2 1.6 ± 0.7* 1.8 ± 0.6*, 1.0 ± 0.8
Angiographic in-stent restenosis (%) 13 ± 7 13 ± 8 11 ± 4 48 ± 17* 51 ± 18*, 43 ± 15*
Histologic in-stent restenosis (%) 18 ± 7 18 ± 8 18 ± 8 52 ± 23* 43 ± 22*, 66 ± 19*
Number in parenthesis indicates number of stent segments per group. BL baseline, FU 5 months follow-up, MLD minimal lumen diameter,
TiNOX titanium-nitride-oxide-coated nitinol stent, UNS uncoated self-expanding nitinol stent
* P \ 0.05 normal-sized vs. oversized
 P = ns UNS vs. TINOX
§ P \ 0.05 baseline vs. 5 months follow-up
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Fig. 3 Change in individual
stent diameter during 5 months
postimplantation for uncoated
nitinol stent segments (left
panel) and titanium-nitride-
oxide-coated nitinol stent
segments (right panel). BL
baseline, FU 5-month follow-
up. Data are given as
mean ± SD
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P \ 0.001; Fig. 2). As for the angiographic results, no
significant differences between uncoated self-expanding
stents segments and TiNOX-coated stents segments were
observed with regard to histomorphometric in-stent reste-
nosis (28 ± 19% vs. 42 ± 29%, P = 0.23). A dot-plot of
angiographic and histomorphometric in-stent restenosis at
5 months against the oversizing ratio among all analyzed
samples are shown in Figs. 5 and 6. Linear regression
analysis showed a positive linear correlation between
oversizing ratio and angiographic (R2 = 0.56, P \ 0.0001)
as well as histomorphometric (R2 = 0.4, P = 0.005) in-
stent restenosis (Figs. 5, 6). Separate analysis for uncoated
self-expanding stent segments and TiNOX-coated stents
segments yielded similar results (Table 1).
Discussion
The data of the present study show that TiNOX-coated self-
expanding nitinol stents are as safe and effective as uncoated
self-expanding nitinol stents in the porcine iliofemoral
artery with an excellent outcome after 5 months in both
groups. The implantation procedure was successful in all
animals, late follow-up was uneventful, and animals showed
no limitations in physical activity and range of motion
during the observed postinterventional period. In the present
study, histomorphometry importantly showed patency in all
samples with open stents in all examined segments. How-
ever, neointimal proliferation of more than 25% was
observed in areas with oversized stent segments (oversizing
ratio C 1.4). During the follow-up period of 5 months,
stents increased in diameter by 6% in the normal-sized and
29% in the oversized group, almost reaching their nominal
diameter under the outward expanding force of the self-
expanding stent. Mean stent expansion after 5 months was
significantly greater for oversized stents. This finding may
be explained by the fact that oversized stents were mostly
deployed in smaller arteries featuring greater counter-force
at implantation [13], but storing higher strain energy in the
stent that leads to pronounced stent expansion over time [8].
Gradual stent expansion for self-expanding stents is known
to be different from balloon-expanding stents. In the latter,
the vessel wall is immediately stretched to its definite
diameter causing instantaneous injury to the artery wall.
Our data support a critical cutoff for oversizing self-
expanding stents at a ratio of 1.4 as recently proposed by
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Fig. 5 A linear correlation of oversizing (nominal stent diameter-to-
artery ratio) and maximal in-stent restenosis obtained by quantitative
angiography at 5 months postimplantation. Dotted line divides
normal-sized from oversized stent segments (nominal stent diame-
ter-to-artery ratio = oversizing factor of 1.4)
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Fig. 6 A linear correlation of oversizing (nominal stent diameter-to-
artery ratio) and maximal in-stent luminal area restenosis obtained by
histomorphometry at 5 months postimplantation. Dotted line divides
normal-sized from oversized stent segments (nominal stent diameter-
to-artery ratio = oversizing factor of 1.4)
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Zhao et al. [8]. Moreover, our results also suggest that this
cutoff point may be valid not only for uncoated self-
expanding nitinol stents but also for self-expanding
TiNOX-coated stents.
Angiographic and histomorphometric follow-up data
observed in our study demonstrate that oversizing linearly
and positively correlates with neointimal proliferation and
in-stent restenosis. A fourfold increase of in-stent reste-
nosis was observed when the oversizing ratio increased by
65%. This phenomenon is unique for self-expanding stents
and has previously been described in coronary and carotid
artery stenting [8, 14–16]. Thus, the benefits of oversizing
self-expanding stents to ensure optimal wall apposition and
to prevent stent migration may be compromised by neo-
intimal proliferation and significant in-stent restenosis. To
our knowledge, Zhao et al. constitute the first and only
group to demonstrate this phenomenon for uncoated self-
expanding stents in porcine iliofemoral arteries [8]. Yet,
they pose the question of whether coated self-expanding
stents may reduce neointima formation in oversized stents.
To address this important issue, we compared uncoated
self-expanding nitinol stents to TiNOX-coated self-
expanding stents. TiNOX-coated stents are biologically
inert compared with the nickel component of nitinol stents.
As previously shown, neointimal hyperplasia was reduced
up to 50% for TiNOX-coated stents compared with stain-
less steel stents in porcine coronary arteries at 6 weeks of
follow-up [10]. In our study, however, adequate sizing was
the most important determinant of in-stent restenosis. For
stents with an oversizing ratio\1.4, in-stent restenosis due
to neointimal proliferation was minimal, and no differences
were observed between uncoated self-expanding nitinol
stents and TiNOX-coated stents. For an oversizing ratio
C1.4 in-stent restenosis occurred to a similar extent in
uncoated self-expanding nitinol stent but also in TiNOX-
coated stents (Fig. 4).
As previously shown, continuing expansion of oversized
self-expanding stents may traumatize the arterial wall
causing injury of the endothelium that is different than
observed with balloon-expanding stent implantation [17].
This leads to an early inflammatory reaction with gradual
infiltration of neutrophils and monocytes. Interactions of
inflammatory cells and stent material lead to a healing
process in which a fibrous capsule and neointimal layer is
formed [8]. Our study indicates that the antiproliferative
feature of TiNOX may not significantly alter this healing
process and restenosis in the iliofemoral artery bed asso-
ciated with oversizing. Because our data were obtained in a
small sample size, they are preliminary and rather obser-
vational. The antiproliferative properties of TiNOX-coated
stents need further investigation in larger studies [10].
Several studies have demonstrated significant improve-
ments with self-expanding nitinol stents compared with
stainless steel stents for peripheral stenting [18, 19]. Thus,
currently self-expanding nitinol stents are most frequently
used for treating patients with peripheral vascular disease.
However, significant restenosis and low patency rates with
peripheral self-expanding nitinol stents, particularly in
superficial femoral artery lesions, still pose a common
clinical problem [20–22]. Initial results for drug-eluting
self-expanding peripheral stents were promising [7, 23,
24]. Unfortunately, subsequent studies with sirolimus- and
everolimus-eluting self-expanding nitinol stents failed to
demonstrate improved mid-term patency compared with
bare-metal stents [24, 25]. These findings were certainly a
surprise, because drug-eluting stents constituted a major
step forward in the treatment of coronary artery disease,
namely a 50–70% reduction in restenosis compared with
bare-metal stents. Several mechanisms may be responsible
for this differential efficacy of drug-eluting stents in cor-
onary versus peripheral arteries.
First, peripheral vessels display an entirely different
remodeling behavior of the vessel wall, following the
placement of self-expanding stents compared with balloon-
expanding stents implanted in coronary arteries [8]. This
may be partly explained by a different anatomy, e.g., the
higher elasticity of the iliofemoral artery compared with
the coronary artery, resulting in a lower degree of instan-
taneous expansion. However, higher strain energy is stored
in the self-expanding stent, which may lead to enhanced
time-dependent expansion, vessel injury, and neointimal
hyperplasia [8, 13]. Moreover, femoral arterial segments
have to face stronger external physical forces, such as
compression, elongation, and torsion that promote reste-
nosis [26]. Differences in blood flow and shear stress in
different vascular regions also have to be considered. These
biologic and mechanical differences may explain why the
potential benefit observed with TiNOX stents compared
with bare-metal stents in the coronary artery bed could not
be reproduced in the iliofemoral arteries in our study
[10, 11]. Of note, clinical investigations have demonstrated
that the concept of TiNOX coating might be superior to
stainless steel stenting [27] but inferior to newer generation
drug-eluting stents with regard to the prevention of reste-
nosis in patients with coronary artery disease [28].
Finally, it is noteworthy that recent data of a new pac-
litaxel-eluting self-expanding nitinol stent were promising
with respect to patency rates; however, only long-term data
will show whether the superiority in terms of efficacy can
be sustained [29].
In summary, as recently proposed by Zhao et al. [8] for
uncoated nitinol stents and now demonstrated by our data
for TiNOX-coated self-expanding nitinol stents, exact
sizing of self-expanding stents without exceeding an
oversizing ratio of 1.4 seems to be crucial for long-term
patency in peripheral artery stenting.
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Limitations
First, the sample size of 15 stents is small. Thus, the current
study may be underpowered to show statistical differences
in restenosis between both stent types. However, certain
restrictions of the local ethical committee regarding the use
of pigs for the current study did not allow a higher number
of study animals. Second, this study was performed in
healthy animals with nonatherosclerotic arteries. Although
the porcine vasculature is very similar to that of humans
[30], our data may not be fully transferred to humans,
particularly not to patients with peripheral artery disease
with different lesion lengths and diameters that may react
variable to TiNOX stenting.
Third, baseline reference vessel diameters were different
between oversizing and normal-sizing stent groups, which
may have impacted in part on the differences in restenosis
that we observed in addition to the effect of stent over-
sizing, potentially due to differences between these vessel
segments per se. However, our data indicate that relevant
restenosis also was observed in larger vessel segments, if
stent-to-artery ratio exceeded 1.3. Fourth, the stents of the
manufacturers had differences in length and diameter,
which was unavoidable, because stents were implanted as
distributed by the vendors at the time of the study. Fifth,
only a single intravenous dose of 250 mg of acetylsalicylic
acid was administered periprocedural, in full accordance
with previously published studies by our group [11], but in
contrast to recent porcine peripheral stent studies imple-
menting dual antiplatelet therapy for 1 month [31].
Although this may increase the propensity for acute and
early stent thrombosis, we did not observe any total
occlusions at follow-up, and no data are available that
would submit a correlation of the length of antiplatelet
therapy and late lumen loss in the absence of stent
thrombosis.
Conclusions
In this experimental model of peripheral endovascular
intervention, we were able to demonstrate that self-
expanding TiNOX-coated stents are as safe and effective as
uncoated self-expanding nitinol stents. Both stent types
were constrained by their target artery at implantation and
expanded over time to near their nominal diameter within
5 months. Severe oversizing determined as an oversizing
ratio C1.4 resulted in significant neointimal proliferation
and in-stent restenosis, which may not be reduced by
TiNOX-coating.
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